OncoSec Medical Gets $13.6M In PIPE

San Diego-based OncoSec Medical, the publicly held biopharmaceuticals firm focused on DNA-based cancer immunotherapy, said Monday that it has raised $13.6M in a registered direct offering of its shares. The company said it will use the new funding for general corporate purposes, including clinical trial expenses, research and development expenses. OncoSec trades on the NASDAQ as ONCS.